Targets › KLRC1
3 programs from 2 companies in 9 trials: 5 Phase 2, 2 Phase 1, 2 Phase 3; Oncology; next expected readout Jan 2027.
Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. (UniProt, P26715)
Open in Phaseline: the race on KLRC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Monalizumab NKG2-A/NKG2-B type II integral membrane protein inhibitor | KLRC1 | Phase 3 | Squamous Cell Carcinoma of the Head and Neck; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Acute Myeloid Leukaemia … | Jan 2027 |
| AstraZeneca | Monalizumab (IPH2201) NKG2-A/NKG2-B type II integral membrane protein inhibitor | KLRC1 | Phase 1 | Advanced Solid Tumors | Jul 2027 |
| Eastern Hepatobiliary Surgery Hospital | Super Hi-TCR-T cells Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP | PVRL4, KLRC1, TROP2, B7H3, GPC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Jan 2028 |
Advanced Solid Tumors (1) Squamous Cell Carcinoma of the Head and Neck (1) Non-Small Cell Lung Cancer (1) Non-small Cell Lung Cancer (1) Acute Myeloid Leukaemia (1) Non-muscle Invasive Bladder Cancer (1) Extensive Stage Lung Small Cell Carcinoma (1) Small Cell Lung Cancer (1) Advanced Hepatocellular Carcinoma (HCC) (1)
mixed (2), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.